

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 December 2000 (14.12.2000)

PCT

(10) International Publication Number  
**WO 00/74649 A3**

(51) International Patent Classification<sup>7</sup>: A61K 31/417.  
31/4045, A61P 27/02

(21) International Application Number: PCT/US00/15379

(22) International Filing Date: 2 June 2000 (02.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/137,564 3 June 1999 (03.06.1999) US

(71) Applicant (for all designated States except US): MAXIM  
PHARMACEUTICALS, INC. [US/US]; Suite 400, 8899  
University Center Lane, San Diego, CA 92122 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): GEHLSSEN, Kurt, R.  
[US/US]; 3333 Lone Hill Lane, Encinitas, CA 92024 (US).

(74) Agent: HUNT, Dale, C.; 16th Floor, 620 Newport Center  
Drive, Newport Beach, CA 92660 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AT  
(utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH,  
CN, CR, CU, CZ, CZ (utility model), DE, DE (utility  
model), DK, DK (utility model), DM, DZ, EE, EE (utility  
model), ES, FI, FI (utility model), GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility  
model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,  
MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,  
SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT,  
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW). Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
17 January 2002

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: OPHTHALMIC HISTAMINE COMPOSITIONS AND USES THEREOF

(57) Abstract: An ophthalmic composition for use in reducing ocular irritation comprising histamine, at a concentration of between about 0.01 and 1.0% by weight, in a pharmaceutically acceptable carrier, adapted for ophthalmic administration.

WO 00/74649 A3

# INTERNATIONAL SEARCH REPORT

In. tional Application No

PCT/US 00/15379

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/417 A61K31/4045 A61P27/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, EMBASE, SCISEARCH, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 95 23601 A (PROFESSIONAL PHARMACEUTICAL IN) 8 September 1995 (1995-09-08)</p> <p>abstract  page 1, line 12 - line 23  page 6, line 22 - line 32  page 9, line 20 - line 25  examples 12,13  page 67, line 28 - line 32  page 69, line 31 -page 70, line 3  claims 1,7,8</p> <p>---</p> <p>-/--</p>	<p>1-3,  6-11,  16-22,  25-27</p>



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

7 August 2001

Date of mailing of the international search report

29/08/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Cielen, E

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/15379

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>US 5 716 610 A (JACK BRUCE A ET AL) 10 February 1998 (1998-02-10)</p> <p>abstract column 1, line 19 - line 49 column 3, line 57 -column 4, line 9 column 5, line 18 - line 23 column 5, line 44 - line 50 examples 12,13 claims 2,4,6,7</p> <p>---</p>	<p>1-3, 6-11, 16-22, 25-27</p>
X	<p>WO 95 13087 A (SCHEPENS EYE RES INST) 18 May 1995 (1995-05-18)</p> <p>abstract page 1, line 29 - line 37 page 7, line 30 -page 8, line 1 page 8, line 20 - line 33 page 9, line 24 - line 29 page 11, line 27 - line 33 page 14, line 7 - line 23 page 15, line 31 -page 16, line 13 example II page 31, line 16 - line 31 table 1 claims 1,3,5,7,8,10,11</p> <p>---</p>	<p>1,3,4, 6-8,10, 16-19, 21-23, 25,27,28</p>
X	<p>WO 99 25341 A (MAXIM PHARM INC) 27 May 1999 (1999-05-27)</p> <p>abstract page 6, line 26 -page 7, line 11 page 8, line 34 - line 36 page 17, line 17 - line 21 page 19, line 31 -page 20, line 16 claims 1-3,8-19</p> <p>---</p>	<p>1-7, 19-24</p>
X	<p>US 4 510 145 A (SCHACHAR RONALD A) 9 April 1985 (1985-04-09) the whole document</p> <p>---</p> <p style="text-align: center;">-/--</p>	<p>1,3-7, 19,21-24</p>

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/15379

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 97 44062 A (ALCON LAB INC ;SHARIF NAJAM (US); GAMACHE DANIEL A (US)) 27 November 1997 (1997-11-27)</p> <p>abstract page 1, line 11 -page 2, line 2 page 4, line 16 - line 22 page 5, line 18 -page 6, line 11 page 7, line 15 -page 8, line 15 page 9, line 13 -page 10, line 8 claims 5,9-11</p>	<p>1,3-8, 10,11, 15, 17-19, 21-25, 27-29</p>
X	<p>WO 98 18458 A (OSBORNE NEVILLE ;DESANTIS LOUIS JR (US); ALCON LAB INC (US); SALLE) 7 May 1998 (1998-05-07)</p> <p>abstract page 1, line 6 - line 10 page 4, line 14 - line 19 page 5, line 7 -page 6, line 19 claim 1</p>	<p>1,3-7, 19,21-24</p>
X	<p>HUI H-W ET AL: "OCULAR DISPOSITION OF TOPICALLY APPLIED HISTAMINE CIMETIDINE AND PYRILAMINE IN THE ALBINO RABBIT" CURRENT EYE RESEARCH, vol. 3, no. 2, 1984, pages 321-330, XP001010645 ISSN: 0271-3683</p> <p>abstract page 321, column 1, paragraph 2 -column 2, paragraph 2 table 3 page 323, column 2, paragraph 2 -page 324, column 1, paragraph 1 page 324, column 2, paragraph 3 -page 325, column 1, paragraph 1 tables 7,8</p>	<p>1-7, 19-24</p>
E	<p>WO 00 40240 A (MAXIM PHARMACEUTICAL INC) 13 July 2000 (2000-07-13)</p> <p>abstract page 3, line 7 - line 11 page 6, line 14 - line 17 page 6, line 34 -page 7, line 34 page 14, line 18 - line 25 page 15, line 16 - line 22 example 6 claims 1,2,4,7,8,19,20,27,30,38</p>	<p>1-13, 17-29</p>

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

Present claims 1, 3-8, 10-19, 21-25, 27-2 relate to compounds and a therapeutic use which actually are not well-defined. The use of the definitions "a histamine receptor analog", "a serotonin analog" and "ocular irritation" in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. The lack of clarity is such as to render a meaningful complete search impossible. Consequently, the search has been restricted to the compounds specifically mentioned in the claims and the examples, i.e. histamine, histamine dihydrochloride, histamine phosphate and serotonin, in relation to the therapeutic uses mentioned on page 3, line 34 - page 4, line 4 and page 4, lines 20-21 and those mentioned in the examples.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/15379

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9523601 A	08-09-1995	EP 0706394 A JP 8509994 T	17-04-1996 22-10-1996
US 5716610 A	10-02-1998	US 5294440 A US 5882639 A US 6080395 A US 5679337 A	15-03-1994 16-03-1999 27-06-2000 21-10-1997
WO 9513087 A	18-05-1995	US 5545617 A AU 1095995 A	13-08-1996 29-05-1995
WO 9925341 A	27-05-1999	US 6071942 A AU 1395599 A CN 1285744 T EP 1047422 A	06-06-2000 07-06-1999 28-02-2001 02-11-2000
US 4510145 A	09-04-1985	US 4390542 A	28-06-1983
WO 9744062 A	27-11-1997	AU 2434297 A	09-12-1997
WO 9818458 A	07-05-1998	AU 4249297 A	22-05-1998
WO 0040240 A	13-07-2000	AU 2721300 A	24-07-2000

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 December 2000 (14.12.2000)

PCT

(10) International Publication Number  
**WO 00/74649 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K 9/00**
- (21) International Application Number: **PCT/US00/15379**
- (22) International Filing Date: **2 June 2000 (02.06.2000)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
**60/137,564** **3 June 1999 (03.06.1999)** **US**
- (71) Applicant (for all designated States except US): **MAXIM PHARMACEUTICALS, INC. [US/US];** Suite 400, 8899 University Center Lane, San Diego, CA 92122 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **GEHLSSEN, Kurt, R. [US/US];** 3333 Lone Hill Lane, Encinitas, CA 92024 (US).
- (74) Agent: **HUNT, Dale, C.;** 16th Floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— Without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**WO 00/74649 A2**

(54) Title: **OPHTHALMIC HISTAMINE COMPOSITIONS AND USES THEREOF**

(57) Abstract: An ophthalmic composition for use in reducing ocular irritation comprising histamine, at a concentration of between about 0.01 and 1.0% by weight, in a pharmaceutically acceptable carrier, adapted for ophthalmic administration.

## OPHTHALMIC HISTAMINE COMPOSITIONS AND USES THEREOF

Field of the Invention

5 The present invention relates to ophthalmic histamine-containing preparations for the treatment of ocular irritation. More precisely, the invention relates to an aqueous formulation of histamine or similar compounds, to be instilled in and around the eye as well as in the conjunctival sac to treat various forms of ocular irritation.

Background of the Invention

10 There are a number of patents that address various ophthalmic formulations to ease ocular irritation. For example, U.S. Patent Nos. 5,895,645; 5,877,154; 5,872,086; and 5,861,148; each recite an ophthalmic solution formulated to ease ocular irritation. However, none of these patents discuss the use of histamine-containing formulations for the reduction of ocular irritation.

Summary of the Invention

15 One embodiment of the present invention is an ophthalmic composition for use in reducing ocular irritation, comprising a compound selected from the group consisting of histamine, a histamine receptor analog, serotonin and a serotonin analog, and a pharmaceutically acceptable ophthalmic carrier. In one aspect of this embodiment, the histamine is histamine dihydrochloride or histamine phosphate. Preferably, the histamine is present at a concentration of between about 0.001% and 10% by weight. More preferably, the histamine is present at a concentration of  
20 between about 0.05% and 5% by weight. Most preferably, the histamine is present at a concentration of between about 0.1% and 1% by weight. In one aspect of this preferred embodiment, the pharmaceutically acceptable carrier is an aqueous solution, gel or ointment. Preferably, the aqueous solution has a pH of between about 6.8 and 7.6.

Another embodiment of the present invention provides a method for treating ocular irritation in a subject in need thereof, comprising administering to the subject an effective ocular irritation-reducing amount of an ophthalmic  
25 composition comprising a compound selected from the group consisting of histamine, a histamine receptor analog, serotonin and a serotonin analog, and a pharmaceutically acceptable ophthalmic carrier. In one aspect of this embodiment, the histamine is histamine dihydrochloride or histamine phosphate. Advantageously, the subject is a human. In one aspect of this embodiment, the ocular irritation is caused by exposure to a pollutant, chemical compound, dust particles, ultraviolet light or a pathogen. The pathogen can be, for example, a virus or bacterium. In  
30 one aspect of this embodiment, the virus is a herpes virus. In another aspect of this embodiment, the bacterium is *Neisseria gonorrhea*. The ocular irritation can be caused by, for example, laser in situ keratomileusis (LASIK), radial keratotomy (RK), photo refractive keratectomy (PRK) or cataract surgery, or an allergic reaction. The compositions described herein can be administered by spraying into the eye, application of an ophthalmic gel or eye drops. Preferably, 1-2 drops of the composition is administered per eye, between 4 and 8 times per day.



Another embodiment of the present invention is a composition comprising a compound selected from the group consisting of histamine, a histamine receptor analog, serotonin and a serotonin analog, and a pharmaceutically acceptable ophthalmic carrier for use in reducing ocular irritation in a subject. In one aspect of this embodiment, the histamine is histamine dihydrochloride or histamine phosphate. The ophthalmic carrier is preferably an aqueous solution, gel or ointment. Preferably, the histamine is present at a concentration of between about 0.001% and 10% by weight. More preferably, the histamine is present at a concentration of between about 0.05% and 5% by weight. Most preferably, the histamine is present at a concentration of between about 0.1% and 1% by weight.

Another embodiment of the present invention provides the use of a composition comprising a compound selected from the group consisting of histamine, a histamine receptor analog, serotonin and a serotonin analog, and a pharmaceutically acceptable ophthalmic carrier for reducing ocular irritation in a subject. In one aspect of this embodiment, the histamine is histamine dihydrochloride or histamine phosphate. Preferably, the histamine is present at a concentration of between about 0.001% and 10% by weight. More preferably, the histamine is present at a concentration of between about 0.05% and 5% by weight. Most preferably, the histamine is present at a concentration of between about 0.1% and 1% by weight.

#### Detailed Description of the Preferred Embodiments

The present invention relates to the use of ophthalmic pharmaceutical formulations comprising histamine for reducing ocular irritation. Ocular irritation can result from various ophthalmic surgical procedures, contact lens wear, exposure to allergens, ocularly irritating chemical compounds, pollutants, dust particles, ultraviolet light, and various pathogenic agents that cause conjunctivitis, including various infections of the eye such as herpetic infections, other viral infections, and bacterial infections. Surprisingly, ophthalmic administration of histamine-containing formulations is effective to reduce ocular irritation.

The histamine-containing formulations described herein preferably comprise histamine dihydrochloride, however, other forms of histamine, such as histamine phosphate, as well as histamine receptor analogs, serotonin and serotonin analogs are also contemplated for use in the present invention.

The histamine is present in the pharmaceutical formulations in an amount effective to reduce ocular irritation. The concentration of histamine, or a similarly functioning compound, in the formulations described herein is expressed in terms of percent histamine by weight of the total composition. For example, in one embodiment, histamine is present in an amount between about 0.001 and 10 percent by weight. In another embodiment, histamine is present in an amount between about 0.05 and 5 percent by weight. In still another embodiment, histamine is present in an amount of between about 0.1 and 1 percent by weight.

The formulations described herein comprise histamine and a pharmaceutically acceptable carrier. In a preferred embodiment, the carrier is a sterile, aqueous solution that is buffered with compounds such as phosphate buffers, carbonate buffers and the like. The composition is preferably provided as a buffered aqueous solution having a viscosity of from about 1 to 50 centipoise (cps). In another preferred embodiment, the composition is formulated as

a viscous liquid having a viscosity of between about 50 and several thousand cps using viscosity-enhancing agents such as, for example propylene glycol, hydroxymethyl cellulose or glycerin.

Other ophthalmic histamine-containing pharmaceutical carriers are also contemplated, including, for example, gels and ointments. The formulations can also comprise ingredients which regulate the osmolarity of the final  
5 formulation, as well as the pH of the formulations.

For example, the resulting preparations for ocular use are advantageously hypotonic, and have an osmolarity of between about 140 and 280 mOsm/l, and a pH of between about 6.8 and 7.6. The osmolarity of the solutions can be adjusted by means of well known osmolarity adjusting agents such as sodium chloride, potassium chloride and monosaccharides. Alternatively, the resulting preparations can be isotonic, or in another embodiment, the resulting  
10 preparations can be hypertonic. The present formulations may also contain other conventional ingredients used in ophthalmic preparations, such as dextrose, preservatives (e.g. Thimerosal™, i.e., sodium ethylmercurithiosalicylate (Sigma; St. Louis, MO), benzalkonium chloride), corticosteroids (e.g. prednisone), analgesics (e.g., ibuprofen), antibiotics (e.g., gentamicin, streptomycin), antioxidants (e.g. ascorbic acid, BHA, BHT), demulcents (e.g., glycerin, propylene glycol), and the like. Descriptions of compounds used in standard ophthalmic formulations may be found in, for  
15 example, *Remington's Pharmaceutical Sciences*, latest edition, Mack Publishing Co., Easton, PA, and in U. S. Patent Nos. 5,951,971, 5,861,148, and 5,800,807.

The pH of the formulations described herein can be adjusted to the desired value by adding an acid, such as hydrochloric acid, or a base such as sodium hydroxide, until the pH of the formulation falls within the range described above. Such adjustments are preferably made without increasing the ionic strength of the formulation to beyond  
20 acceptable levels.

The present histamine-containing compositions are prepared according to conventional techniques by mixing the relative ingredients in appropriate amounts in sterile water, or preparing histamine-containing gels and ointments using gel and ointment preparation techniques well known in the pharmaceutical arts. In preferred embodiments, the formulations are sterilized prior to use.

The ophthalmic formulations described herein are administered to the eyes of a subject, preferably an animal such as a dog, cat, bird, reptile or amphibian, more preferably a mammal, most preferably a human, by any route and through any means where delivery of the histamine content of the formulation to the site of ocular irritation can be achieved. For example, the formulations are administered by spray, by ophthalmic gel, by eye drop, by injection within  
25 the eye, or by other methods of administration well known to those of skill in the relevant art. In one embodiment of the present invention, daily dosages in human therapy of the present ophthalmic formulations are of about 1-2 drops per eye, administered about 1-8 times a day (for instance by means of a standard pharmacopeial medicinal dropper of 3 mm in external diameter, which when held vertically delivers 20 drops of water of total weight of 0.9-1.1 grams at 25°C.)  
30

The formulations described herein can be used to reduce ophthalmia or eye inflammation resulting from  
35 contact lens wear, or conditions such as uveitis, iritis, allergic reactions such as severe hay fever, watery eyes,

conjunctivitis such as ocular bacterial infections and ocular viral infections. Various forms of conjunctivitis include: gonococcal conjunctivitis, a form of conjunctivitis caused by the bacterium *Neisseria gonorrhea*, Inclusion Conjunctivitis, a form of conjunctivitis caused by the bacterium *Chlamydia trachomatis*, vernal keratoconjunctivitis, keratoconjunctivitis sicca, episcleritis, scleritis, and the like.

5           Conjunctivitis or inflammation of the conjunctiva can be caused by a number of factors including an allergic reaction to dust, mold, animal dander, pollen, or other allergens, and can be irritated by wind, dust, smoke, and other types of air pollution. The conjunctiva may also be irritated by a common cold or a bout of measles. The ultraviolet light of an electric welding arc, sunlamp, or even bright sunlight reflected by snow or water can irritate the conjunctiva. Conjunctivitis can also be caused by problems with the tear ducts, sensitivity to chemicals, exposure to  
10           irritants, and infection by particular bacteria--typically chlamydia. Conjunctivitis can last for months or years.

          When irritated, the conjunctiva becomes bloodshot, and a discharge often appears in the eye. In bacterial conjunctivitis, the discharge may be thick and white or creamy. In viral or allergic conjunctivitis, the discharge is usually clear. The eyelid may swell and itch intensely, especially in allergic conjunctivitis.

          Usually conjunctivitis is easy to recognize because it commonly occurs with a cold or allergies. Sometimes,  
15           however, conjunctivitis resembles iritis, a more severe eye inflammation, or even acute glaucoma--serious conditions that can lead to a loss of vision. A doctor can usually distinguish the diseases. With the more serious eye conditions, the blood vessels closest to the colored part of the eye (iris) are very inflamed. Although conjunctivitis may cause a burning sensation, it is usually less painful than the more serious conditions. Conjunctivitis almost never affects vision unless the discharge temporarily covers the cornea.

20           The formulations described herein can also be used to reduce ocular irritation caused by a variety of ocular surgical techniques including LASIK, PK, PRK, and cataract surgery.

#### EXAMPLES

          Particular aspects of the invention can be more readily understood by reference to the following examples,  
25           which are intended to exemplify the invention, without limiting its scope to the particular embodiments.

##### Example 1

##### Treatment of Watery Eyes Caused by Exposure to an Allergen

          A subject exposed to an allergen and presenting ocular irritation as a result is administered an aqueous histamine-containing formulation containing 0.01% histamine dihydrochloride by weight. The subject is administered 2  
30           drops per eye every three hours or as necessary to relieve the ocular irritation.

##### Example 2

##### Treatment of Watery Eyes Caused by Exposure to a Pollutant

          A subject exposed to a pollutant and presenting ocular irritation as a result is administered an aqueous histamine-containing formulation containing 0.1% histamine dihydrochloride by weight. The subject is administered 4  
35           drops per eye every three hours or as necessary to relieve the ocular irritation.

Example 3Treatment of Watery Eyes Caused by Contact Lens Wear

A subject presenting ocular irritation as a result of contact lens wear is administered an aqueous histamine-containing formulation containing 0.05% histamine dihydrochloride by weight. The subject is administered 2 drops per eye every three hours or as necessary to relieve the ocular irritation.

Example 4Gonococcal Conjunctivitis

Gonococcal conjunctivitis is a gonococcal infection of the eye. Newborns can acquire a gonococcal infection of the conjunctiva from their mother while passing through the birth canal. For this reason, most states require that all newborns receive eyedrops--often silver nitrate, povidone iodine, or an antibiotic ointment such as erythromycin--to kill the bacteria that could cause gonococcal conjunctivitis. Adults can contract gonococcal conjunctivitis during sexual activity if, for example, infected semen gets into the eye. Usually only one eye is involved.

Within 12 to 48 hours after the infection starts, the eye becomes red and painful. If the infection isn't treated, ulcers can form on the cornea, an abscess can develop, the eyeball can become perforated, and even blindness can result.

A subject presenting the symptoms of gonococcal conjunctivitis is treated with a histamine-containing spray formulation with 0.05% histamine dihydrochloride by weight and also containing antibiotics effective against gonorrhea. The spray is administered to the subject 2 times per day for four to six weeks.

Example 5Trachoma

Trachoma (granular conjunctivitis, Egyptian ophthalmia) is a prolonged infection of the conjunctiva caused by the bacterium *Chlamydia trachomatis*. Trachoma is common in poverty-stricken parts of the dry, hot Mediterranean countries and the Far East. It occurs occasionally among Native Americans and among people in mountainous areas of the southern United States. Trachoma is contagious in its early stages and may be transmitted by eye-hand contact, by certain flies, or by contaminated articles such as towels and handkerchiefs.

In the early stages of the disease, the conjunctiva is inflamed, reddened, and irritated, and a discharge appears. In the later stages, the conjunctiva and cornea become scarred, causing the eyelashes to turn inward and vision to become impaired.

A subject diagnosed with trachoma is administered three times daily a histamine-containing formulation of the present invention in the form of an ophthalmic gel containing .02% by weight histamine phosphate and tetracycline or erythromycin for 4 to 6 weeks.

Example 6Photo Refractive Keratectomy (PRK)

Photo refractive keratectomy (PRK) is the sculpting of a myopic or hyperopic lens for refractive reasons on the front surface of the eye with the use of a "cold" laser light. Utilizing the accuracy and precision of the excimer laser, PRK changes the shape of the cornea to improve the refraction of a subject's eyes.

A subject having received PRK is treated with a histamine-containing formulation in the form of eyedrops containing 0.025% histamine phosphate. The subject applies 2 drops four times daily to each eye for up to five weeks to reduce ophthalmic irritation caused by the PRK procedure.

Example 7Radial keratotomy (RK)

Radial keratotomy (RK) is a surgical procedure that changes the shape of the front of the eye with microscopic incisions oriented in a "radial" or spoke-like pattern around the outside of the cornea. This procedure, and a variation of RK called astigmatic keratotomy (AK) can reduce or eliminate nearsightedness and astigmatism by flattening the cornea. This allows light to focus more directly on the retina.

A subject who has recently received RK is treated with a histamine-containing formulation of the present invention in the form of eyedrops with histamine dihydrochloride at a final concentration of 0.2% by weight. The subject applies 2 drops four times daily for three weeks to each eye to reduce ophthalmic irritation caused by the RK procedure.

Example 8Laser in Situ Keratomileusis (LASIK)

LASIK is a surgical operation for the treatment of refractive errors by reshaping tissue beneath the surface of the cornea. With LASIK, a flap of surface cornea is cut and rolled aside in order that a laser beam can remove internal tissue from the inside (stroma or body) of the cornea. Once the flap has been created the excimer laser is used to reshape the cornea underneath the flap. Following removal of tissue the surface layer is reattached. The amount and shape of the removed tissue is determined by the preoperative refractive error i.e. myopia, hyperopia or astigmatism.

A subject who has recently received LASIK is treated with a histamine-containing formulation of the present invention in the form of a spray. The spray contains 0.5% histamine dihydrochloride by weight. The subject applies 2 sprays of the formulation four times daily to each eye for six weeks to reduce ophthalmic irritation caused by the LASIK procedure.

While particular embodiments of the invention have been described in detail, it will be apparent to those of skill in the relevant art that these embodiments are exemplary, rather than limiting. The true scope of the invention is that defined within the attached claims and equivalents thereof. All references cited herein are hereby expressly incorporated by reference.

WHAT IS CLAIMED IS:

1. An ophthalmic composition for use in reducing ocular irritation comprising a compound selected from the group consisting of histamine, a histamine receptor analog, serotonin and a serotonin analog, and a pharmaceutically acceptable ophthalmic carrier.
- 5 2. The composition of Claim 1, wherein said histamine is histamine dihydrochloride or histamine phosphate.
3. The composition of Claim 1, wherein said histamine is present at a concentration of between about 0.001% and 10% by weight.
4. The composition of Claim 1, wherein said histamine is present at a concentration of between about  
10 0.05% and 5% by weight.
5. The composition of Claim 1, wherein said histamine is present at a concentration of between about 0.1% and 1% by weight.
6. The composition of Claim 1, wherein said pharmaceutically acceptable ophthalmic carrier is selected from the group consisting of an aqueous solution, gel and ointment.
- 15 7. The composition of Claim 6, wherein said aqueous solution has pH of between about 6.8 and 7.6.
8. A method for treating ocular irritation in a subject in need thereof, comprising administering to said subject an effective ocular irritation-reducing amount of an ophthalmic composition comprising a compound selected from the group consisting of histamine, a histamine receptor analog, serotonin and a serotonin analog, and a pharmaceutically acceptable ophthalmic carrier.
- 20 9. The method of Claim 8, wherein said histamine is histamine dihydrochloride or histamine phosphate.
10. The method of Claim 8, wherein said subject is a human.
11. The method of Claim 8, wherein said ocular irritation is caused by exposure to an agent selected from the group consisting of a pollutant, chemical compound, dust particles, ultraviolet light and pathogen.
- 25 12. The method of Claim 8, wherein said pathogen is selected from the group consisting of a virus and a bacterium.
13. The method of Claim 12, wherein said virus is a herpes virus.
14. The method of Claim 12, wherein said bacterium is *Neisseria gonorrhea*.
15. The method of Claim 8, wherein said ocular irritation is caused by an ophthalmic surgical technique  
30 selected from the group consisting of laser in situ keratomileusis (LASIK), radial keratotomy (RK), photo refractive keratectomy (PRK), and cataract surgery.
16. The method of Claim 8, wherein said ocular irritation is caused by an allergic reaction.
17. The method of Claim 8, wherein said composition is administered by a method selected from the group consisting of spraying into the eye, application of an ophthalmic gel and eye drops.

18. The method of Claim 8, wherein said composition is in solution and said administering comprises administering 1-2 drops of said composition per eye, between 4 and 8 times per day.

19. A composition comprising a compound selected from the group consisting of histamine, a histamine receptor analog, serotonin and a serotonin analog, and a pharmaceutically acceptable ophthalmic carrier for use in  
5 reducing ocular irritation in a subject.

20. The composition of Claim 19, wherein said histamine is histamine dihydrochloride or histamine phosphate.

21. The composition of Claim 19, wherein said ophthalmic carrier is selected from the group consisting of an aqueous solution, gel and ointment.

10 22. The composition of Claim 19, wherein said histamine is present at a concentration of between about 0.001% and 10% by weight.

23. The composition of Claim 19, wherein said histamine is present at a concentration of between about 0.05% and 5% by weight.

15 24. The composition of Claim 19, wherein said histamine is present at a concentration of between about 0.1% and 1% by weight.

25. Use of a composition comprising a compound selected from the group consisting of histamine, a histamine receptor analog, serotonin and a serotonin analog, and a pharmaceutically acceptable ophthalmic carrier in the preparation of a medicament for reducing ocular irritation in a mammal.

26. The use of Claim 25, wherein said histamine is histamine dihydrochloride or histamine phosphate.

20 27. The use of Claim 25, wherein said histamine is present at a concentration of between about 0.001% and 10% by weight.

28. The use of Claim 25, wherein said histamine is present at a concentration of between about 0.05% and 5% by weight.

25 29. The use of Claim 25, wherein said histamine is present at a concentration of between about 0.1% and 1% by weight.

**THIS PAGE BLANK (USPTO)**